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Abstract: Ovarian carcinoma, the most lethal gynecological cancer, is characterized by late diagnosis,
with drug resistance limiting the efficacy of platinum-based therapy. Since some integrins are
upregulated in cancer, including ovarian carcinoma, they represent a potential target for drug delivery.
Receptor tyrosine kinases are also deregulated in cancer and their expression has been associated with
drug resistance. Here, the antitumor effects of three conjugates possessing a selective binder of the
extracellular portion of integrin αVβ3 covalently linked to the tyrosine kinase inhibitor sunitinib were
investigated in cisplatin-sensitive and -resistant ovarian carcinoma cells expressing both tyrosine
kinase VEGFR2 and αVβ3 at different levels. We found that one of the three compounds was active
in inhibiting the growth of both drug-sensitive and -resistant cells in the micromolar range with a
slightly increased potency in resistant cells as compared to sunitinib. The same compound markedly
impaired cell migratory and invasive abilities and reduced paxillin phosphorylation. Antitumor
activity studies in IGROV-1/Pt1 cells xenografted in nude mice revealed a striking activity of this
conjugate versus sunitinib. Taken together, our results support the interest of integrin-targeted
sunitinib conjugates for the treatment of drug-resistant tumors.
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1. Introduction
Ovarian carcinoma is the most lethal gynecological cancer as it is often diagnosed at an advanced
stage [1]. Early detection increases the probability of a favorable prognosis, but it is not frequent
due to lack of early disease symptoms. Late diagnosis makes the disease difficult to cure in spite
of the initial efficacy of platinum-based treatment [2,3]. In fact, a persistent response to treatment
is not achieved and drug resistance is developed [4,5]. The pathways sustaining drug resistance of
ovarian carcinoma are multiple and involve, among the diverse factors, drug accumulation impairment,
loss of DNA mismatch repair, increased nucleotide excision repair, and hyperactivation of receptor
tyrosine kinases (RTKs) [5–7]. Such receptors, frequently deregulated in cancer, are implicated in the
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regulation of multiple processes including cell survival and angiogenesis [8]. The latter phenomenon
is mainly sustained by vascular endothelial growth factor receptor (VEGFR) activation, as shown
by several reports in different cancer types [9]. Targeting of angiogenesis is already pursued in
the clinics in ovarian cancer, as shown by the approval of the anti-VEGF antibody Bevacizumab as
frontline treatment after surgery. Although anti-angiogenesis therapy in ovarian cancer has been
shown to prolong disease-free survival [10], there is an urgent need to identify novel anti-angiogenic
drugs with minimal side-effects. In this context, an innovative approach is represented by the use of
tumor-targeting strategies aimed at delivering both conventional and targeted drugs selectively to
tumor cells [11,12]. This approach has already generated promising preclinical results translatable to
the clinical setting [13–15].
The use of selective binders of the extracellular portion of integrin αVβ3 covalently linked to
targeted agents may result in the selective inhibition of tumor cell growth and, given the pattern of
overexpression of αVβ3 also present in endothelial cells, these conjugates represent an opportunity for
a dual targeting strategy impairing the microenvironment ability to sustain tumor cell growth.
Recently, a new class of molecular conjugates was launched, where the αVβ3 integrin binder
c(AmpRGD) [16,17] (alias aminoproline-based RGD cyclotetrapeptide) was covalently connected to
the anti-tumor and anti-angiogenic RTK inhibitor sunitinib (compounds 1–3, Figure 1) [18]. These
compounds proved chemically robust, competent, and selective binders of αVβ3-overexpressing
endothelial progenitor cells and melanoma cells, capable of (at least partially) entering these cells and
inhibiting their proliferation. Furthermore, they demonstrated an ability to impair tumor-associated
angiogenesis in vitro and in vivo, and to significantly decrease xenografted melanoma tumor growth
in mice [18,19].
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Based on this background, the present study was designed to selectively target ovarian carcinoma
cells characterized by ag essive features in terms of re pon e to treatm nt (i. ., drug resist nce)
and pro-invasive behavior. We elected to use conjugates 1–3 in thi endeav r considering that (i)
the integrin-recognizing moiety could ensure cell-selective accumulation on αVβ3-overexpress
ovarian carcinoma cells and possibly provide internalization via int grin-mediated endocytosis, (ii)
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once entered the cells, the sunitinib moiety could be available to exert its intracellular inhibitory effect,
and (iii) the overall conjugates could alter the αVβ3-VEGFR2 crosstalk thus impacting the downstream
intracellular pathways related to these receptors [18,19].
We demonstrated that conjugates 1–3 inhibited the growth and migration ability of cisplatin-sensitive
ovarian carcinoma cells at low micromolar concentrations. Furthermore, conjugate 3 was able to inhibit
cell growth and markedly reduce the migration potential of cisplatin-resistant ovarian carcinoma
cells, even better than sunitinib. Compounds 1–3 reduced the phosphorylation of paxillin, a focal
adhesion-associated, phosphotyrosine-containing protein implicated in VEGF signaling [20].
We also showed that conjugate 3 significantly decreased the growth of cisplatin-resistant carcinoma
cells implanted in nude mice as compared to sunitinib even at lowered dosage, supporting the notion
that these integrin-targeted sunitinib conjugates can be promising tools against drug-resistant tumors.
2. Results
2.1. Synthesis of Conjugates 1–3
The molecular conjugates 1–3 and the unconjugated reference compound c(AmpRGD) (Figure 1)
were prepared according to reported procedures [17,18].
2.2. Levels of VEGFR2
Deregulated expression of receptor tyrosine kinases (RTKs) may have a prognostic relevance in
ovarian carcinoma and activation of survival pathways downstream of RTKs is known to be involved
in cellular drug resistance both to conventional drugs and to targeted agents [5,6]. Thus, we examined
the expression of VEGFR2 in cisplatin-sensitive and -resistant cells by western blot analysis. We found
that VEGFR2 was expressed in various ovarian carcinoma cell lines including IGROV-1, IGROV-1/Pt1,
and the two drug-resistant variants of A2780 cells (A2780/BBR and A2780/CP) (Figure 2).
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2.3. Cell Sensitivity of Cisplatin-Sensitive and -Resistant IGROV-1 Ovarian Carcinoma Cell Lines
The three conjugates 1–3, as well as their parent compound c(AmpRGD), are characterized
by selective binding capability toward the αVβ3 integrin receptor, as previously demonstrated in
both cell-free and cellular assays [17–19]. Specifically, the binding competence of these compounds
toward the isolated αVβ3 receptor was proven, with IC50 values in the competitive displacement of
biotinylated vitronectin, a natural ligand of the αVβ3 receptor, being comprised in the low nanomolar
range (compound 1, IC50 αVβ3 1.24 nM, compound 2, IC50 αVβ3 5.1 nM, compound 3, IC50 αVβ3
3.8 nM, c(AmpRGD), IC50 αVβ3 6.1 nM) [17,18]. Thus, it was demonstrated that the presence of both
the sunitinib moiety and the linker did not compromise the good αVβ3-integrin targeting capability
of these covalent conjugates [18]. These compounds were also assayed for their ability to inhibit the
adhesion to vitronectin of both αVβ3-overexpressing and αVβ3-lacking cells (namely, αVβ3-positive
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endothelial progenitor cells EPCs and melanoma cells M21, as well as αVβ3-lacking human prostate
carcinoma cells PC3 and human erythroleukemia cells K562); the results showed that conjugates 1–3
inhibited cell adhesion to vitronectin of αVβ3-overexpressing cells in the low micromolar range, while
the c(AmpRGD) parent compound did not impact at all on cell adhesion to vitronectin in αVβ3-lacking
cells [18,19].
Based on these precedents, and considering that (i) both cisplatin-sensitive IGROV-1 cell line
and its cisplatin-resistant IGROV-1/Pt1 counterpart express VEGFR2 (vide supra); (ii) both IGROV-1
and IGROV-1/Pt1 cells express the αVβ3 integrin, with the latter expressing higher levels of the αVβ3
integrin as compared to parental cells (Figure S1) [13]; and (iii) IGROV-1/Pt1 cells exhibit a stable
drug-resistant phenotype with a degree of cisplatin resistance of 11.5, the sensitivity of these IGROV-1
and IGROV-1/Pt1 cells to the three conjugates 1–3 was assessed by growth inhibition assays after 72 h
drug exposure (Figure 3).
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assays. Cells were seeded and 24 h later exposed to the co pounds for 72 h. Cells were then counted
using a cell counter. IC50 is defined as the concentration inhibiting cell growth by 50%. The IC50 values
of the c(AmpRGD) per se were 6.04 ± 2.8 µM in IGROV-1 cells and >30 µM in IGROV-1/Pt1 cells.
Sensitivity relative to sunitinib is: 1.59, 4.00, 2.01 for compounds 1, 2, and 3, respectively, in IGROV-1
cells, and 3.88, 5.28, 0.86 for compounds 1, 2, and 3, respectively, in IGROV-1/Pt1 cells.
The three conjugates exhibited a marked capability to inhibit cell growth in the parental cell
line, the IC50 values being in the low micromolar range in the IGROV-1 cell line, whereas a reduced
inhibitory eff ct was observed for compounds 1 and 2 in IGROV-1/Pt1 cells (for 1, p = 0.0017; for 2,
p = 0.0039 by two-ta l Student’s t-test, n = 3). In fact, only c mpound 3 was active in the low micromolar
range in the cisplatin-resistant cell line and, differently from the other conjugates, this compound
tended to display marginally reduced sensitivity as compared to IGROV-1 cells ( = 0.054 , by
two-tail Student’s t-test, n = 3). Cell sensitivity to the parent unconjugated c(AmpRGD) ligand and to
sunitinib was also examined for comparison. The c(AmpRGD) ligand displayed an inhibitory effect
in the parental cell line but not in the resistant variant. The growth inhibitory activity of sunitinib
was decreased in the platinum-resistant cells (p = 0.0086, by two-tail Student’s t-test, n = 4) to a larger
extent than conjugate 3, whose activity was comparable to that of sunitinib. In parental cells, on the
other hand, a slightly reduced effect was observed for conjugate 3 as compared to sunitinib, (p = 0.0106
by Student’s t-test, n = 3).
2.4. Modulation of Cell Migratory and Invasive Abilities and Modulation of Downstream Targets of VEGFR2 of
Cisplatin-Sensitive and -Resistant IGROV-1 Ovarian Carcinoma Cell Lines
Because VEGFR2 is implicated in sustaining tumor aggressiveness, in particular cell migration
and invasive abilities [20,21], we examined the effects of all conjugates on these aggressive cell features
(Figure 4). IGROV-1/Pt1 cells displayed a significantly higher migratory and invasive potential as
compared to parental cells (p < 0.05, unpaired Student’s t-test). Cells were exposed for 24 h to
Cancers 2019, 11, 531 5 of 13
concentrations of agents (10 µM) unable to affect viability at that time and—using transwell assays—we
found that all (and the sole) RGD-containing molecules were able to inhibit cell migration of both cell
lines and, in particular, compound 3 produced the most striking effect in almost completely inhibiting
migration of resistant cells (Figure 4a). As for the modulation of invasiveness (Figure 4b), while
IGROV-1 cells were not inhibited at all by RGD-containing molecules, cisplatin-resistant cells resulted
inhibited by both sunitinib and RGD-compounds to almost the same extent.
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2.5. Cell Sensitivity and Modulation of Cell Migratory and Invasive Abilities of Cisplatin-Sensitive A2780
Ovarian Carcinoma Cell Line
In the perspective of developing therapeutic approaches precisely tailored to tumor cell alterations,
we extended the analysis of selected effects of the conjugates under investigation to the A2780 cell line
which displays still detectable levels of VEGFR2, but lower than those of IGROV-1/Pt1 cells (Figure 2).
These cells also express reduced levels of the αVβ3 integrin as compared to IGROV-1/Pt1 cells, as
shown by flow cytometry analysis (Figure S1). Thus, the sensitivity of the A2780 ovarian carcinoma
cell line to sunitinib and the three conjugates 1–3 was firstly assessed by growth inhibition assays after
72 h drug exposure (Table S3). All the tested compounds were active in the low micromolar range,
with sunitinib-linked conjugates 1 and 3 behaving similarly to sunitinib. In addition, A2780 cells were
exposed for 24 h to concentrations of agents (0.3 µM) unable to affect viability and, using transwell
assays, we found that the sunitinib-containing molecules, both the free drug and RGD-conjugates 1–3,
were able to inhibit cell migration and invasion, while the sole RGD molecule showed pro-invasive
and pro-migratory behavior (Figure S2).
2.6. In Vivo Antitumor Activity
Given the promising results displayed by conjugate 3 in vitro, the antitumor activity of compound
3 as compared to sunitinib and cisplatin was assayed in nude mice bearing s.c. the IGROV-1/Pt1 human
ovarian carcinoma. The results are shown in Table 1 and Figure 6. Sunitinib could highly impair tumor
growth of IGROV-1/Pt1 xenografts with a TVI value of 84% (p < 0.0001, 20 days after cell injection,
Student’s t-test of control versus sunitinib, n = 7). Interestingly, even though endowed with a load of
sunitinib about nine times lower, compound 3 was still able to induce a TVI of 60% (p < 0.0001, 20 days
after cell injection, Student’s t-test of control versus compound 3, n = 7). Treatment was well tolerated.
No toxic death occurred in treated mice. Cisplatin administered according to its clinical route produced
a TVI of 67% (p < 0.0001, 20 days after cell injection, Student’s t-test of control versus cisplatin, n = 7).
Table 1. Effects of i.p. compound 3, oral sunitinib and intravenous cisplatin in nude mice s.c. bearing
the IGROV-1Pt1 human ovarian carcinoma.
Drug Days of Treatment Dose (mg/Kg) TVI 2 p 3 vs. Controls BWL% 4 Tox 5
Compound 3 4–8, 11–15, 18–22, 25–27 20 60 0.0001 1 0/7
Sunitinib 4–8, 11–15, 18–22, 25–27 40 84 0.0001 0 0/7
Cisplatin 4, 11, 18 4.5 67 0.0001 0 0/7
1 Tumor cells (107/mouse) were s.c. inoculated into the right flank on day 0. Treatment started when tumors were
not measurable. 2 Tumor volume inhibition % in treated over control mice assessed 20 days after cell injection.
3 By two-tail Student’s t-test. 4 Body weight-loss percentage induced by treatment; the highest value is reported.
5 Dead/treated mice.
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Figure 6. Antitumor activity of conjugate 3 in IGROV-1/Pt1 tumors. The effects of i.p. compound 3,
20 mg/kg (havin a sunitinib-equivalent loading 9 ti es lower than parental sunitinib), ral sunitinib,
40 mg/kg, qd×5/w×4w and intravenous cisplatin (4.5 mg/Kg, q7d×3) were evaluated on the growth of
the IGROV-1/Pt1 carcinoma cells s.c. injected into the right flank of female nude mice (107 cells/mouse)
on day 0. Treatment started on day 4: compound 3 (open up triangle), sunitinib (filled square), cisplatin
(down triangle) or control (open circle). Experimental groups consisted of seven animals. Growth
curves of the tumors are shown. Points report mean values of tumor volumes. Bars: SD.
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To investigate the vascular alterations induced by the treatment, we performed an
immunohistochemistry analysis of microvessels evaluating CD31 positivity in tumor samples collected
after treatment with compound 3, sunitinib, and control mice. We observed that endothelial area (CD31
positive area) was significantly lower in tumor samples obtained from mice treated with conjugate 3 or
sunitinib than control animals, indicating an anti-angiogenic effect of the two molecules (p < 0.05 by
ANOVA followed by Bonferroni test) (Figure 7).
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3. Discussion
Small molecule-drug conjugates represent a recent class of drugs with the potential to target
tumor-specific or overexpressed antigens [11,12,22,23]. Since both RTK and some integrin subtypes such
as αVβ3 are overexpressed in cancer cells, agents directed to both these targets appear to be extremely
promising, also taking into account the tumor targeting properties of integrin ligands [18,19,24]. In
particular, αVβ3 and VEGFR2, which are expressed in ovarian cancer, are implicated in signaling
networks sustaining tumor cell survival and angiogenesis. Although ovarian carcinoma is not a
frequent cancer, its outcome is poor because of its diagnosis as advanced disease and the development
of drug resistance. Such resistance can be sustained by multiple mechanisms, including loss of DNA
mismatch repair and enhanced nucleotide excision repair which in principle might also be sustained
by the activation of survival pathways [25].
In the present study, we used different αVβ3- and VEGFR2-positive ovarian carcinoma cell
lines including drug-resistant variants to test the effects of conjugates 1–3 made by the covalent
junction of a selective binder of the extracellular portion of integrin αVβ3 to the RTK inhibitor
sunitinib. The αVβ3 binder was obtained from a series of aminoproline-based RGD cyclotetrapeptides
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of type c(AmpRGD) (Figure 1), as previously reported [16,17]. A selective and marked binding
capability of both unconjugated and variously conjugated c(AmpRGD)-containing molecules toward
the αVβ3 integrin receptor has been previously reported by us in both cell-free and cell-based
assays [14,17–19,26]. Furthermore, c(AmpRGD)-sunitinib conjugates 1–3 were previously proven to
be partially internalized in both endothelial progenitor cells and M21 melanoma cells, and an active
role of integrin αVβ3 during cell uptake was demonstrated [18,19]. In addition, c(AmpRGD)-sunitinib
conjugate 3 demonstrated good inhibitory activity against human recombinant VEGFR2 in the
nanomolar range [18], demonstrating that the covalent conjugation of these two moieties could
preserve the targeting abilities of the individual components.
In this study, we investigated the effects of conjugates 1–3 on both cisplatin-sensitive IGROV-1
and cisplatin-resistant IGROV-1/Pt1 cells that were found to express VEGFR2 (Figure 2). In addition,
the drug-resistant cell line has been previously shown to display increased αVβ3 levels as compared
to the parental one [13] (Figure S1), and was therefore considered a unique model to investigate the
efficacy of these dual compounds. The three conjugates displayed a marked antiproliferative activity
in parental cells, with IC50 values in the low micromolar range, as shown by growth inhibition assays
(Figure 3). The activity of compounds 1 and 2 was markedly reduced in cisplatin-resistant cells, while
conjugate 3 maintained its antiproliferative activity even more than sunitinib.
An increased aggressiveness of IGROV-1/Pt1 cells in terms of migratory and invasive abilities has
been linked to Axl overexpression [27]. Of note, here we observed that all conjugates 1–3 were capable
of inhibiting cell migration in both IGROV-1 and IGROV-1/Pt1, with a striking effect of compound 3 on
the migratory ability of resistant cells that was almost completely abolished (Figure 4). An inhibition
of cell invasive ability was also observed. It has to be noted that the drug concentrations used for
these experiments were equimolar (10 µM) and cells seeded for evaluation of migratory and invasive
capability were viable.
Moreover, the A2780 cell line, exhibiting detectable levels of VEGFR2 and levels of αVβ3 lower
than IGROV-1/Pt1 cells, was also examined in cell migration and invasion assays, and we found that,
again, conjugates 1–3 (at 0.3 µM concentrations) displayed the capability to inhibit cell aggressiveness,
although to a reduced extent than in IGROV-1/Pt1 cells. Taken together, these results suggest that this
class of compounds might be useful in ovarian carcinoma as novel therapeutic agents, but it appears
to be important to consider the level of expression of VEGFR2 and αVβ3 to target cells coexpressing
both targets.
An interesting observation emerging from western blot analysis was the capability of the
conjugated compounds 1–3 to reduce paxillin phosphorylation, evident in cisplatin-sensitive cells, and
still achievable in the cisplatin-resistant cells at both 10 µM and 3 µM concentrations (Figure 5 and
Table S2). Outside-in signaling via growth factor receptors and integrins has been shown to involve
both non-RTKs such as c-Src, and RTKs, with triggering of signaling resulting in activation of PI3
kinase-Akt and canonical MAPK pathways [20]. Paxillin is a scaffold protein acting by recruiting
signaling proteins to the plasma membrane and when it is phosphorylated by FAK or Src, additional
binding sites for adaptor proteins are generated; the inhibition of its phosphorylation is therefore
relevant to reduce the activation of oncogenic pathways with key roles in cancer cell proliferation and
chemoresistance such as Akt and ERK1/2.
Given the interesting results obtained in these in vitro assays by conjugated compounds 1–3,
and in particular considering the good performance of compound 3 in inhibiting cell growth and
preventing tumor cell aggressiveness in vitro, this last dual conjugate 3 was elected as the most
promising candidate for advancing in vivo studies. The IGROV-1/Pt tumor model, in which cisplatin
—usually displaying a marked activity in ovarian cancer xenografts—exhibited a significant but not
striking activity due to the acquired resistant phenotype (Table 1 and Figure 6), was used for an
evaluation of antitumor activity. In this regard, it has to be highlighted that compound 3 was used
at 20 mg/Kg since this dose was previously shown to be well-tolerated by mice [18,19] and also to
evaluate the impact of the in vivo treatment using a dosage expected to be devoid of toxicity. Sunitinib,
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instead, was tested at its optimal dose using the clinically relevant route, i.e., oral administration [28,29].
Under such conditions, the dose of the sunitinib moiety within conjugate 3 was around 9 (8.86) times
lower than that delivered to mice treated with sunitinib malate (Figure 6). Thus, although the TVI
observed for sunitinib-treated mice (84%) was greater than that of compound 3-treated mice (60%),
these results strongly support the tumor inhibitory potential of this conjugate. In keeping with the
observed antitumor activity, when examining endothelial area (Figure 7), we observed a striking effect
induced by compound 3, as well as sunitinib, in impairing microvessel structure.
4. Materials and Methods
4.1. Drugs
Cisplatin (Teva Pharma Italia S.r.l., Nerviano, Italy) was diluted in saline. Sunitinib (as malate salt,
>99% purity, Selleckchem, Munich, Germany) was dissolved and diluted in DMSO. Conjugates 1–3
and c(AmpRGD) (as TFA salts, 96–98% purity after semipreparative reverse-phase HPLC purification)
were synthesized according to reported procedures [17,18]. For in vivo studies, compound 3 and
cisplatin were dissolved in saline, and sunitinib was dissolved in DMSO and carboxymethylcellulose
0.5% (10% and 90%, respectively). Drugs were delivered in a volume of 10 mL/kg of body weight.
4.2. Cell Lines and Growth Conditions
The human ovarian carcinoma cell lines IGROV-1 (from Dr. Benard, Villjuif, France), A2780 (from
Prof. Ozols, Bethesda, MD, USA), and the cisplatin-resistant variants—IGROV-1/Pt1, A2780/CP, and
A2780/BBR—were obtained as previously described and were cultured in RPMI-1640 medium (Lonza,
Basel, Switzerland), supplemented with 10% FBS (Gibco, Life Technologies, Carlsbad, CA, USA) [30,31].
Cells were thawed from frozen stocks and cultured for no more than 20 passages. Cell identity was
authenticated through microsatellite analysis by the AmpFISTR Identifiler PCR Amplification Kit
(Applied Biosystem, Carlsbad, CA, USA). Cell sensitivity to drugs was measured by growth inhibition
assays based on cell counting. At 24 h after seeding, cells were exposed to the drugs for 72 h. Cells were
counted with a cell counter at the end of drug incubation. IC50 is defined as the drug concentration
producing 50% decrease of cell growth. Statistical analysis to compare IC50 values was carried out
by two-side Student’s t-test using GraphPad Prism (version 5.02, GraphPad Software Inc., La Jolla,
CA, USA).
4.3. Cell Migration and Invasion Assays
Cell migration and invasion assays were carried out as previously described [27]. Cells were
seeded in complete medium and treated for 24 h with drug concentrations not affecting viability in that
time period. Cells were transferred (8 × 105 per well) to 24-well transwell chambers (Costar, Corning,
Inc., Corning, NY, USA) in serum-free medium. For invasion assays, the transwell membranes were
previously coated with 60 µL of 208 mg/mL matrigel per well (BD Biosciences, San Jose, CA, USA) and
dried for 1 h. After 24 h of incubation at 37 ◦C, cells that migrated to the lower chamber or invaded the
matrigel and then migrated to the lower chamber were fixed in 95% ethanol, stained with a solution of
0.4% sulforhodamine B (SRB, Sigma-Aldrich, Milan, Italy) in 0.1% acetic acid, and counted under an
inverted microscope. Each experiment was carried out in triplicate, counting three fields per sample.
4.4. Western Blot Analyses
Western blot analysis was carried out as previously reported, with minor modifications [27].
Cells were harvested using a scraper and lyzed in a buffer composed of 0.125 M Tris HCl pH 6.8
(Sigma-Aldrich), 5% sodium dodecyl sulfate (SDS, Lonza, Verviers, Belgium) and protease/phosphatase
inhibitors (Sigma-Aldrich). Protein samples were boiled for 5 min, sonicated for 25 s and quantified
through the BCA assay method (Pierce, Thermo Fisher Scientific, Monza, Italy). Equal amounts
of proteins were fractionated by SDS-PAGE and blotted on nitrocellulose membranes. Blots were
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pre-blocked in PBS containing 5% (w/v) dried nonfat milk and then incubated overnight at 4 ◦C
with primary antibodies. Immunoreactive bands were revealed by enhanced chemiluminescence
detection system ECL (GE Healthcare, Little Chalfont, UK). Antibody binding to blots was detected
by chemiluminescence. The anti VEGFR2 antibody was from Bioss (Aurogene SRL, Rome, Italy), the
anti-paxillin and anti-phosphopaxillin antibodies were form Abcam Limited (Cambridge, UK) and
Upstate Biotechnology (Lake Placid, NY, USA), respectively. Vinculin and tubulin (Sigma-Aldrich)
were used as loading control. Quantification of band intensity was performed using the ImageJ 1.47v
software (http://imagej.nih.gov/ij), which attributes a numeric value to the band intensity. Each value is
then normalized with respect to its loading control and the ratio between each sample and the control
was calculated.
4.5. Analysis of Integrin Levels
The expression of integrins was measured by flow cytometry, as previously described [13].
Exponentially growing cells were harvested and incubated for 30 min at 4 ◦C with anti-human αvβ3
(Millipore Merck, Milan, Italy) or isotypic control (Sigma-Aldrich). Cells were then washed, and
samples were immediately used for flow cytometric analysis (BDAccuri C6, Becton-Dickinson, Milan,
Italy). Expression of integrins was expressed as the ratio between the mean fluorescence intensity
obtained in cells incubated with the anti-integrin antibody divided by that of cells incubated with
isotypic control.
4.6. Antitumor Activity Evaluation
All experiments were carried out using female athymic CD-1 nude mice, 8–10 weeks-old (Charles
River, Calco, Italy). Mice were maintained in laminar flow rooms keeping temperature and humidity
constant. Mice had free access to food and water. Experiments were authorized by the Italian
Ministry of Health according to the national law (Project Identification: 1103/2015-PR.; approved by
the Ministry of Health on 10 October 2015) in compliance with international policies and guidelines.
The IGROV-1Pt1, cisplatin-resistant variant of the IGROV-1 human ovarian carcinoma, was used as
xenograft in the study. Exponentially growing cells (107/mouse) were s.c. injected into the right flank
on day 0 forming experimental groups of seven animals. Tumor take was 100%. Tumor growth was
followed by biweekly measurements of tumor diameters with a Vernier caliper. Tumor volume (TV)
was calculated according to the formula: TV (mm3) = d2 × D/2 where d and D are the shortest and the
longest diameter, respectively. Treatment started 4 days after cell inoculum, when tumors were not
measurable. Compound 3, 20 mg/kg i.p., and sunitinib, 40 mg/kg orally, were administered daily for 5
days a week for 4 weeks (qd × 5/w × 4w). Cisplatin (4.5 mg/Kg) was administered by i.v. three times
every 7 days. The efficacy of the drug treatment was assessed as tumor volume inhibition percentage
(TVI%) in treated versus control mice, calculated as: TVI% = 100−(mean TV treated/mean TV control
× 100). Toxic effects of the treatment were determined as body weight loss and lethal toxicity. The
highest body weight loss percentage induced by treatments is reported in Table 1. Deaths occurring in
treated mice before the death of the first control mouse were ascribed to toxic effects. Student’s t-test
(two-tailed) was used for statistical comparison of tumor volumes in mice.
4.7. Immunohistochemistry and Digital Image Analysis
Subcutaneous IGROV-1/Pt1 xenograft samples from the three groups were collected 24 h after the
last treatment, fixed in 10% neutral buffered formalin and paraffin embedded for histopathological
analyses. 4 µm sections from each sample were stained by immunohistochemistry to detect
tumoral vessels with the rat anti-CD31 antibody (clone SZ31, Dianova, DIA310, dilution 1:100).
For immunohistochemistry, deparaffinization, rehydration and antigen retrieval were performed
in a single step method: sections were immersed for 40 min at 94 ◦C in a pH 9 buffer solution
(Dewax and HIER Buffer H, Thermo Scientific). Endogenous peroxidase activity was blocked by
incubating sections in 3% H2O2 for 15 min. To reduce nonspecific background staining, slides were
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rinsed and treated, for 30 min, with 10% normal rabbit serum and then incubated for 1 h at room
temperature with the primary antibody. A rabbit anti-rat biotinylated secondary antibody (BA-4001,
Vector Laboratories-DBA Italia, Milan, Italy) was then added for 30 min and sections were labeled by
the avidin-biotin-peroxidase (ABC) procedure with a commercial immunoperoxidase kit (Vectastain
Standard Elite, Vector Laboratories). The immunoreaction was developed with 3,3′-diaminobenzidine
substrate (DAB, Vector Laboratories) for 5 min and sections were counterstained with Mayer’s
hematoxylin. The tumor-associated vasculature was evaluated in each sample by measuring the
percentage of CD31-immunolabeled area (endothelial area) in three 200×microscopic fields, randomly
selected throughout the neoplastic tissue, using ImageJ software.
4.8. Statistical Analyses
Statistical analyses were carried out using GraphPad Prism (version 5.02, GraphPad Software Inc.,
La Jolla, CA, USA), as detailed throughout the manuscript.
5. Conclusions
Since αV integrins and VEGFR2 can be overexpressed on the surface of ovarian cancer cells,
here we evaluated rationally designed dual conjugates characterized by the capability to both target
αVβ3 integrin-expressing tumors and to inhibit VEGFR2. Our approach reflects the need to tailor
treatment to the specific molecular alterations of tumors cells and to direct the drug to the tumor
site, two major goals in the perspective of a personalized treatment devoid of relevant side effects.
In vitro growth inhibition assays in cisplatin-sensitive and -resistant ovarian carcinoma cells showed
remarkable activity associated with strong inhibition of aggressive cell features. Inhibition of tumor cell
aggressiveness was not limited to cellular models expressing high levels of VEGFR2 and αVβ3 integrin,
since it was observed even in cell types expressing lower but still detectable levels of these receptors.
In vivo evaluation of conjugated compound 3 supported the promising features of this agent,
since a marked antitumor activity was found in the cisplatin-resistant model using a dose of conjugate
corresponding to a drug loading 9 times lower than the dose of sunitinib malate administered at its
optimal dose. Also, significant vascular alterations induced by the treatment with compound
3 emphasized an anti-angiogenic effect in the tumor microenvironment. Due to the effective
intervention of compound 3 toward drug-resistant cells by exploitation of specific tumor cell alterations,
interesting perspectives may be opened, pointing to the use of dual conjugates of type 3 in the
cisplatin-resistant ovarian carcinoma clinical setting, as either anti-tumor/anti-angiogenesis agents per
se, or in combination with cisplatin. Further studies are necessary, however, to deeply investigate drug
combination schedules and mechanisms underlying their interaction.
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